EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
W. Wick, et al.
2022 ESMO Immuno-Oncology Congress
Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
W. Wick, et al.
2022 ESMO Immuno-Oncology Congress
EO2401 therapeutic vaccine for patients with recurrent glioblastoma Phase 1/2 ROSALIE study
D. Reardon, et al.
2022 SNO Annual Meeting
Strong immune response to therapeutic vaccination EO2401 microbiome-derived vaccine + nivolumab – Interim report of the EOGBM1-18/ROSALIE study
A. Maia, et al.
2022 SITC Annual Meeting
Relevant Literature
*authored by Enterome
OncoMimics approach
The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
C. Gouttefangeas, et al.
Frontiers in Immunology, June 2023
*Drug discovery in the age of deep sequencing
C. Bonny
MedNous, May 2022
A very high level of crossreactivity is an essential feature of the T-cell receptor
D. Mason
Immunology today, September 1998
Cross-reactivity of T cells and its role in the immune system
G. Petrova, et al.
Critical Reviews in Immunology, March 2012
Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire
V. l. Zarnitsyna, et al.
Frontiers in Immunology, December 2013
Why must T cells be cross-reactive?
A. Sewell, et al.
Nature Reviews Immunology, August 2012
Challenges in the development of effective peptide vaccines for cancer
C. Buteau, et al.
Mayo Clinic Proceedings, April 2002
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
M. Sioud, et al.
Scandinavian Journal of Immunology, January 2018
Pre-existing heterologous T-cell immunity and neoantigen immunogenicity
Q. Leng, et al.
Clinical & Translational Immunology, March 2020
Effector and Memory T cell Responses to Commensal Bacteria
Y. Belkaid, et al.
Trends Immunology, June 2013
EndoMimics approach
Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs
S. Fetissov, et al.
Current Medicinal Chemistry, October 2017
Gut microbiota in human metabolic health and disease
Y. Fan, et al.
Nature Reviews Microbiology, September 2020
IL-10 produced by macrophages regulates epithelial integrity in the small intestine
T. Morhardt, et al.
Scientific reports, February 2019
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
W. Ouyang, et al.
Immunity, April 2019
Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
Tomaro-Duchesneau, et al.
Scientific Reports, March 2020
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Yoon, et al.
Nature Microbiology, April 2021
Mapping interactions of microbial metabolites with human G-protein-coupled receptors
Colosimo, et al.
Cell, Host & Microbe, August 2019
Computational platform
*GeneMark-HM: improving gene prediction in DNA sequences of human microbiome
A. Lomsadze, et al.
NAR Genomics and Bioinformatics, June 2021
*Scalable workflow and reproductible data analysis for genomics
F. Strozzi, et al.
Methods in molecular biology, July 2019
*MSP-Miner-abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data
F. Onate, et al.
Bioinformatics, May 2019
*A unified catalog of 204,938 reference’ genomes from the human gut microbiome
A. Almeida, et al.
Nature biotechnology, July 2020
*Incorporating phylogenetic information in microbiome differential abundance studies has no effect on detection power and FDR control
A. Bichat, et al.
Frontiers in microbiology, April 2020
A metagenomic strategy for harnessing the chemical repertoire of the human microbiome
Sugimoto, et al.
Science, December 2019
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Asnicar, et al.
Nature Medicine, January 2021
*Impact of laparoscopic Roux-enY gastric bypass and sleeve gastrectomy on gut microbiota – a metagenomic comparative analysis
W. Farin, et al.
Surgery for obesity and related diseases, March 2020
Focus on inflammatory diseases
*Identification of a muropeptide precursor transporter from gut microbiota and its role in preventing intestinal inflammation
S. Liuu, et al.
PNAS, December 2023
*Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
F.P. Oñate, et al.
International Journal of Molecular Sciences, September 2023
*Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation
N. Tchitchek, et al.
JCI Insight, September 2022
*Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease
G. Chevalier, et al.
Microbiome, August 2021
*Antimicrobial resistance profiles of adherent invasive Escherichia coli show increased resistance to B-lactams
M. Martinez-Medina, et al.
Antibiotics, May 2020
*Gut microbiota diversity is reduced in smokers with Crohn’s disease
J. Opstelten, et al.
Inflammatory bowel diseases, September 2016
Focus on the gut microbiome impact on human health
*Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in NAFLD
S. Burz, et al.
Microorganisms, January 2021
*The human gut microbiome as source of innovation for health: which physiological and therapeutic outcomes could we expect?
J. Doré, et al.
Therapy, February 2017
Downloads
MSPminer
The binary is freely available for non-commercial users
Enterome France
Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex